Group President, Global Innovative Pharma Business
Geno Germano is Group President of Pfizer’s Global Innovative Pharma Business, the company’s operating unit focused on development, registration and commercialization of novel, value creating medicines that significantly improve patients’ lives. In this role, Germano leads a growing global business with market-leading medicines and a robust pipeline in several therapeutic areas including inflammation, cardiovascular and metabolic disease, neuroscience and pain and rare diseases. Additionally, Germano is Co-Chair of the Portfolio Strategy and Investment Committee which focuses on maximizing the return on research and development investment across the Pfizer Inc. portfolio. Germano is a member of Pfizer’s Executive Leadership Team.
Additionally, Germano manages Pfizer’s Global Health and Value function created to demonstrate the value of innovation and support access to Pfizer medicines. Global Health and Value includes experts from market access, health economics, outcomes research and real world data focused on ways to improve patient outcomes and reduce total healthcare costs.
Previously, Germano served as President and General Manager of Pfizer’s Specialty Care and Oncology business units.
Joining Pfizer from Wyeth Pharmaceuticals, Germano served as President of the U.S. and Pharmaceutical business units and was responsible for the U.S. Pharmaceuticals, Biologics and Vaccines businesses. In addition, he led the global strategy for the Pharmaceutical and Institutional business units.
With more than 25 years of international experience in the pharmaceutical industry, Germano has held many positions including Executive Vice President and General Manager for Wyeth Global Vaccines; Managing Director, Wyeth Australia and New Zealand and Executive Vice President and General Manager of the Pharmaceutical business unit. He led numerous product launches in primary and specialty care therapeutic areas. Germano also held various commercial development and strategy positions at Johnson & Johnson companies. Prior to joining the pharmaceutical industry, Germano was a pharmacist, where he first developed his zeal for science that makes a difference for patients.
Germano is a member of the G50, an executive group that seeks to promote openness among business leaders and to create economic and social progress in the region. Also, he serves as a member of the Board of the Biotechnology Industry Organization (BIO); on the Advisory Board of the Healthcare Businesswomen's Association and as a Trustee of the Albany College of Pharmacy where he received his Bachelor of Science degree in Pharmacy.